Blood Test Can Predict Alzheimer's Risk Up to 10 Years Before Symptoms Appear

A newly FDA-cleared blood test measuring phosphorylated tau 217 (p-tau217) offers the potential to identify individuals at risk of developing Alzheimer's disease a decade before cognitive symptoms appear. This breakthrough biomarker test could revolutionize early detection and intervention strategies for one of the most common forms of dementia. However, researchers caution that questions remain about the test's accuracy in predicting whether cognitively healthy individuals will actually develop cognitive impairment. The test represents a significant advancement in Alzheimer's research, potentially allowing doctors to intervene earlier and help patients plan their care proactively.